Monday, October 09, 2017 8:53:20 PM
The company is set to make a presentation at The Liver Meeting 2017 slated for October 20-24, 2017 in Washington D.C.
Go look at page 16 slides in company presentation "CB4209 reduces Liver Fat
(Steatosis)--See slide 3
Recent CWBR News
- CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K) • Business Wire • 11/27/2023 11:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 10:21:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:01:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 01:05:22 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 10/25/2023 01:01:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2023 01:00:42 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 10/06/2023 08:13:20 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 10/06/2023 08:11:18 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 10/04/2023 01:14:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 01:12:48 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2023 04:15:25 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/12/2023 08:47:59 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 09/12/2023 05:44:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:07:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:05:38 PM
- CohBar Reports Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/14/2023 08:01:05 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 08/10/2023 09:30:56 PM
- Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) • GlobeNewswire Inc. • 06/05/2023 12:05:22 PM
- Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 05/30/2023 12:05:15 PM
- CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy • GlobeNewswire Inc. • 05/23/2023 11:30:39 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM